PMID- 11094868
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20061115
IS  - 1081-5589 (Print)
IS  - 1081-5589 (Linking)
VI  - 48
IP  - 6
DP  - 2000 Nov
TI  - In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and 
      leukocyte activation markers in inflammatory bowel disease.
PG  - 449-56
AB  - BACKGROUND: Interleukin-10 (IL-10) exhibits potent anti-inflammatory and 
      immunosuppressive activities in vitro. Recent data indicate that treatment with 
      recombinant human IL-10 (rHuIL-10) Crohn's disease is safe and may induce 
      clinical and endoscopic remission. The present study investigates the in vivo 
      immunomodulatory properties of rHuIL-10 in inflammatory bowel disease (IBD). 
      METHODS: As part of two randomized, double-blinded, placebo-controlled trials, 
      repeated flow cytometric analyses of lymphocyte phenotypes (CD3, CD4, CD8, CD16 + 
      56, CD19) and activity markers (human leukocyte antigen [HLA]-DR; intercellular 
      adhesion molecule-1 [ICAM-1]; IL-2-receptor alpha [IL-2R alpha]; high affinity 
      receptor for immunoglobulin G [IgG; Fc gamma RI]) on T cells, monocytes, and 
      neutrophils were performed in 17 patients with IBD who received rHuIL-10 (5, 10, 
      or 20 micrograms/kg) or placebo, administered subcutaneously, once daily for 28 
      days. RESULTS: Minor changes were noted in CD3+, CD8+, and CD3+/CD16 + 56+ 
      lymphocyte phenotypes, whereas absolute numbers of CD4+ lymphocytes and CD19+ 
      cells increased. T-cell activation markers HLA-DR and IL-2R alpha were 
      downregulated. rHuIL-10 did not influence HLA-DR expression on monocytes. ICAM-1 
      modulation on monocytes and neutrophils was mild and inconsistent. Fc gamma RI 
      expression was upregulated on both neutrophils and monocytes. CONCLUSIONS: These 
      data indicate that the immunosuppressive effects of rHuIL-10 treatment are partly 
      different from its in vitro observed actions. The increase of the 
      cytotoxicity-mediating Fc gamma RI points to potential immunostimulating 
      properties of this cytokine.
FAU - Dejaco, C
AU  - Dejaco C
AD  - Department of Internal Medicine IV, University of Vienna, Austria. 
      clemens.dejaco@akh-wien.ac.at
FAU - Reinisch, W
AU  - Reinisch W
FAU - Lichtenberger, C
AU  - Lichtenberger C
FAU - Waldhoer, T
AU  - Waldhoer T
FAU - Kuhn, I
AU  - Kuhn I
FAU - Tilg, H
AU  - Tilg H
FAU - Gasche, C
AU  - Gasche C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American 
      Federation for Clinical Research
JID - 9501229
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Receptors, IgG)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Recombinant Proteins)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Female
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Immunophenotyping
MH  - Immunosuppressive Agents/*pharmacology
MH  - Inflammatory Bowel Diseases/*immunology
MH  - Intercellular Adhesion Molecule-1/analysis
MH  - Interleukin-10/*pharmacology
MH  - Lymphocytes/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Receptors, IgG/analysis
MH  - Receptors, Interleukin-2/analysis
MH  - Recombinant Proteins/pharmacology
EDAT- 2000/11/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/30 11:00
PHST- 2000/11/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/30 11:00 [entrez]
PST - ppublish
SO  - J Investig Med. 2000 Nov;48(6):449-56.